Sources of Funding: This study was initiated and funded by Pfizer Animal Health, New York, NY, USA.
A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis
Article first published online: 21 NOV 2013
© 2013 Zoetis Inc. Veterinary Dermatology published by John Wiley and sons on behalf of the ESVD and ACVD.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Volume 24, Issue 6, pages 587–e142, December 2013
How to Cite
Cosgrove, S. B., Wren, J. A., Cleaver, D. M., Walsh, K. F., Follis, S. I., King, V. I., Tena, J.-K. S. and Stegemann, M. R. (2013), A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis. Veterinary Dermatology, 24: 587–e142. doi: 10.1111/vde.12088
Conflict of Interest: All authors are current or former employees of Zoetis Inc. (formerly Pfizer Animal Health).
- Issue published online: 21 NOV 2013
- Article first published online: 21 NOV 2013
- Manuscript Accepted: 6 SEP 2013
- Pfizer Animal Health
- 1VPI® Pet Insurance website. Top 10 pet medical conditions of 2010. Available at: http://press.petinsurance.com/pressroom/02222011Pet_Conditions_2010.aspx. Accessed Dec 28, 2012.
- 9Dermatologic therapy. In: Muller and Kirk's Small Animal Dermatology. 7th ed. St Louis: Saunders Elsevier, 2013; 150–153., , .
- 10Glucocorticoid agents, general information. In: Plumb’s Veterinary Drug Handbook. 4th ed. Ames: Blackwell Publishing, 2002; 387–389..
- 13Oclacitinib (Apoquel®; Zoetis) is a novel Janus kinase inhibitor that has activity against canine pro-allergic and pro-inflammatory cytokines. Vet Dermatol 2013; 24: 384–385. (abstract)., , et al.
- 17Comparison of the janus kinase (JAK) inhibitor, oclacitinib, and prednisolone in canine models of pruritus. Vet Dermatol 2012; 23(Suppl 1): 38 (abstract)., , et al.
- 19Apoquel® product label. Available at: https://online.zoetis.com/US/EN/Products/Documents/Apoquel_PI.pdf. Accessed Jul 16, 2013.
- 20International Co-operation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH), Good Clinical Practice Website. Available at: http://www.vichsec.org/en/topics.htm. Accessed Dec 28, 2012.
- 24Re-evaluation of diagnostic criteria of canine atopic dermatitis. Rev Med Vet (Toulouse) 1998; 149: 1057–1064., , et al.
- 26Treatment of atopic eczema with staphylococcal toxoid. J Am Med Assoc 1988; 259: 2759–2760..
- 27Single and multiple dose pharmacokinetics of oclacitinib maleate in the dog. In: Proceedings of the American Academy of Veterinary Pharmacology and Therapeutics Biennial Meeting. Potomac, MD, USA: 2013., , et al.
- 33Efficacy of a 0.0584% hydrocortisone acetate spray (Cortavance) for the management of pedal pruritus in atopic dogs; a pilot study. Vet Dermatol 2008; 19(Suppl 1): 40 (abstract)., , et al.
- 38Margin of safety study of oclacitinib maleate administered to adult laboratory dogs for 26 weeks at multiples of the therapeutic dose. In: Proceedings of the American Academy of Veterinary Pharmacology and Therapeutics Biennial Meeting. Potomac, MD, USA: 2013., , et al.
- 39Chapter 16: Mast cell tumors. In: Withrow SJ, MacEwen EG, eds. Saunders Small Animal Clinical Oncology. 3rd edition. Philadelphia: W.B. Saunders Co., 2001; 261–282., .
- 40Novartis Animal Health website. Atopica [indications]. Available at: http://www.ah.novartis.com/products/en/atopica_dog.shtml. Accessed Jan 25, 2013.
- 41Committee for Medicinal Products for Veterinary use (CVMP). Guidelines on statistical principles for veterinary clinical trials. EMA/CVMP/EWP 20 September 2010. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/01/WC500120834.pdf. Accessed Sept 13, 2013.
- 42Inconsistent definitions for intention-to-treat in relation to missing outcome data: systematic review of the methods literature. PLoS One. website. Available at http://dx.doi.org/10.1371%2Fjournal.pone.0049163. Accessed Aug 20, 2013., , et al.